


SUPPLEMENTARY MATERIALS


**Novel 1-amidino-4-phenylpiperazines as potent agonists at human TAAR1 receptor: rational design, synthesis, biological evaluation and molecular docking studies**

Valeria Francesconi <sup>1</sup>, Elena Cichero <sup>1,\*</sup>, Evgeny V. Kanov <sup>2</sup>, Erik Laurini <sup>3</sup>, Sabrina Pricl <sup>3,4</sup>, Raul R. Gainetdinov <sup>2,5</sup> and Michele Tonelli <sup>1,\*</sup>


**Table S1.** Chemical structure and biological activity of 2-aminoxazolines (**1b-37b**) acting as *h*TAAR1 agonists previously exploited for QSAR analyses [30].




Comp.	R	A	R1	Configuration	pEC <sub>50</sub> (M)
<b>1b</b>	H	-CH <sub>2</sub> -	2-Cl	<i>S</i>	6.81
<b>2b</b>	H	-CH <sub>2</sub> -	H	<i>S</i>	6.48
<b>3b</b>	H	-CH <sub>2</sub> -	H	<i>R</i>	5.54
<b>4b</b>	H	-CH <sub>2</sub> CH <sub>2</sub> -	3-Cl	<i>S</i>	7.74
<b>5b</b>	H	-CH <sub>2</sub> CH <sub>2</sub> -	H	<i>S</i>	7.57
<b>6b</b>	CH <sub>3</sub>	-CH <sub>2</sub> CH <sub>2</sub> -	3-Cl	<i>S</i>	6.48
<b>7b</b>	H	-CH <sub>2</sub> O-	3-Cl	<i>S</i>	6.57
<b>8b</b>	H	-CH <sub>2</sub> NH-	3-Cl	<i>S</i>	6.24
<b>9b</b>	H	-CH <sub>2</sub> NCH <sub>3</sub> -	3-Cl	<i>S</i>	7.57
<b>10b</b>	H	-CH <sub>2</sub> NC <sub>2</sub> H <sub>5</sub> -	3-Cl	<i>S</i>	7.54
<b>11b</b>	H	-CH <sub>2</sub> NC <sub>2</sub> H <sub>5</sub> -	H	<i>S</i>	7.23
<b>12b</b>	H	-CH <sub>2</sub> N <sup><i>i</i></sup> Pr-	H	<i>S</i>	6.85
<b>13b</b>	H	-CH <sub>2</sub> NC <sub>2</sub> H <sub>5</sub> -	H	<i>R</i>	6.64



Comp.	R	pEC <sub>50</sub> (M)
<b>14b</b>	( <i>S</i> )-CH <sub>3</sub>	5.81
<b>15b</b>	( <i>R</i> )-CH <sub>3</sub>	6.14
<b>16b</b>	( <i>S</i> )-C <sub>2</sub> H <sub>5</sub>	7.74
<b>17b</b>	( <i>R</i> )-C <sub>2</sub> H <sub>5</sub>	5.65



Comp.	A	pEC <sub>50</sub> (M)
<b>18b</b>	-CH <sub>2</sub> CH <sub>2</sub> CH <sub>2</sub> -	7.57
<b>19b</b>	-CH <sub>2</sub> OCH <sub>2</sub> -	6.44
<b>20b</b>	-CH <sub>2</sub> CH <sub>2</sub> O-	8.05




Comp.	R	R1	R2	R3	Configuration	pEC <sub>50</sub> (M)
<b>21b</b>	H	H	H	H	<i>S</i>	7.17
<b>22b</b>	H	Cl	H	H	<i>S</i>	7.64
<b>23b</b>	H	H	Cl	H	<i>S</i>	7.68
<b>24b</b>	H	H	H	Cl	<i>S</i>	6.84
<b>25b</b>	H	H	Cl	Cl	<i>S</i>	7.51
<b>26b</b>	H	H	H	Br	<i>S</i>	6.82
<b>27b</b>	H	H	H	Br	<i>R</i>	5.00
<b>28b</b>	CH <sub>3</sub>	Cl	H	H	<i>S</i>	6.78
<b>29b</b>	CH <sub>3</sub>	H	H	Br	<i>S</i>	7.39
<b>30b</b>	H	H	H	Ph	<i>S</i>	5.57
<b>31b</b>	H	H	OPh	H	<i>R/S</i>	5.71
<b>32b</b>	H	H	F	H	<i>S</i>	6.31
<b>33b</b>	H	CH <sub>3</sub>	H	H	<i>S</i>	7.17
<b>34b</b>	H	CH <sub>3</sub>	H	Cl	<i>S</i>	7.96
<b>35b</b>	H	CH <sub>2</sub> CH <sub>3</sub>	H	Cl	<i>S</i>	7.59
<b>36b</b>	H	<i>c</i> Pr	H	Cl	<i>S</i>	7.92
<b>37b</b>	H	CH <sub>3</sub>	F	H	<i>S</i>	7.77


**Table S2.** Table of scoring functions for the selected docking poses of the discussed *hTAAR1* agonists.

Compound	S	E_conf	E_place	E_score1	E_refine	E_score2
<b>20b</b>	-99.1078	-109.1025	-10.3802	-5.6912	-33.6487	-99.1078
<b>26b</b>	-96.2118	-108.1425	-10.5221	-5.1112	-31.4564	-96.2118
<b>27b</b>	-87.6534	-102.8943	-8.9768	-6.7823	-28.8635	-87.6534
<b>30b</b>	-84.7643	-107.8932	-9.0065	-7.6523	-28.6522	-84.7643
<b>1</b>	-85.7222	-319.0324	-11.0525	-5.1549	-22.5136	-85.7222
<b>2</b>	-94.6754	-310.7677	-11.0066	-6.4366	-28.9887	-94.6754
<b>6</b>	-94.5612	-280.4532	-12.6753	-5.7821	-27.9911	-94.5612
<b>15</b>	-95.0332	-281.8556	-12.7560	-6.2340	-29.0032	-95.0332
<b>PEA</b>	-95.8775	-109.6754	-9.6544	-4.7865	-27.7765	-95.8775


**Figure S1.** Docking positioning of the oxazoline derivative **20b** (C atom, yellow) and  $\beta$ -PEA (C atom; green) at the *hTAAR1* putative binding site. Ligands are shown in sticks. The most relevant residues are labelled.




**Figure S2.** Docking positioning of the oxazoline derivative **30b** at the *hTAAR1* putative binding site is shown as ligplot. The most relevant residues are labelled, being represented the most relevant H-bonds experienced by the agonist.



**Figure S3.** Docking positioning of the amidine derivative **1** (C atom, yellow) and **PEA** (C atom; green) at the *hTAAR1* putative binding site. Ligands are shown in sticks. The most relevant residues are labelled.


























**Figure S4.** Docking positioning of the amidine derivative **2** (C atom, orange) and **15** (C atom; magenta) at the *h*TAAR1 putative binding site. Ligands are shown in sticks. The most relevant residues are labelled.







**Table S3.** Analysis of the ChEMBL database depending on different similarity thresholds to the present 1-amidino-4-phenylpiperazines **1-16**.

Compounds	First similar structures from ChEMBL database
	<p data-bbox="927 1368 1158 1406">Similarity 67.74%</p> <p data-bbox="927 1585 1158 1624">Similarity 66.66%</p>
	<p data-bbox="895 1944 1190 2027">Threshold: 60% no records were found</p>

 <p style="text-align: center;"><b>3</b></p>	<p style="text-align: center;">Similarity 71.42%</p>  <p style="text-align: center;">CHEMBL4172220 *</p>
 <p style="text-align: center;"><b>4</b></p>	<p style="text-align: center;">Similarity 73.68%</p>  <p style="text-align: center;">CHEMBL4163065 *</p>
 <p style="text-align: center;"><b>5</b></p>	<p style="text-align: center;">Similarity 100.0%</p>  <p style="text-align: center;">CHEMBL1215544</p> <p style="text-align: center;">Similarity 70.59%</p>  <p style="text-align: center;">CHEMBL4173769 *</p>
 <p style="text-align: center;"><b>6</b></p>	<p style="text-align: center;">Similarity 74.36%</p>  <p style="text-align: center;">CHEMBL4169509 *</p>
 <p style="text-align: center;"><b>7</b></p>	<p style="text-align: center;">Similarity 75.0%</p>  <p style="text-align: center;">CHEMBL4177366 *</p>




 <p style="text-align: center;"><b>8</b></p>	<p style="text-align: center;">Similarity 72.97 %</p>  <p style="text-align: center;">CHEMBL4172905 *</p>
 <p style="text-align: center;"><b>9</b></p>	<p style="text-align: center;">Similarity 75.61%</p>  <p style="text-align: center;">CHEMBL4161604 *</p>
 <p style="text-align: center;"><b>10</b></p>	<p style="text-align: center;">Similarity 72.97%</p>  <p style="text-align: center;">CHEMBL4162232</p> <p style="text-align: center;">Similarity 71.43%</p>  <p style="text-align: center;">CHEMBL296963</p>
 <p style="text-align: center;"><b>11</b></p>	<p style="text-align: center;">Similarity 68.0%</p>  <p style="text-align: center;">CHEMBL4162640</p>
 <p style="text-align: center;"><b>12</b></p>	<p style="text-align: center;">Threshold: 60%</p> <p style="text-align: center;">no records were found</p>
 <p style="text-align: center;"><b>13</b></p>	<p style="text-align: center;">Similarity 59.46%</p>  <p style="text-align: center;">CHEMBL1463766</p>

 <p style="text-align: center;"><b>14</b></p>	<p style="text-align: center;">Similarity 68.75 %</p>  <p style="text-align: right;">CHEMBL1215544</p>
 <p style="text-align: center;"><b>15</b></p>	<p style="text-align: center;">Threshold: 70% no records were found</p>
 <p style="text-align: center;"><b>16</b></p>	<p style="text-align: center;">Threshold: 70% no records were found</p>




\* Piperazino-based biguanides (SET2) previously synthesized by the Authors; see REF 31 (CHEMBL4145505): Guariento, S.; Tonelli, M.; Espinoza, S.; Gerasimov, A.S.; Gainetdinov, R.R.; Cichero, E. Rational design, chemical synthesis and biological evaluation of novel biguanides exploring species-specificity responsiveness of TAAR1 agonists. *Eur. J. Med. Chem.* **2018**, *146*, 146 171-184






$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(2-Chlorophenyl)piperazine-1-carboximidamide hydrochloride (3)






$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(2-Methoxyphenyl)piperazine-1-carboximidamide hydrochloride (6)






$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(3-Methoxyphenyl)piperazine-1-carboximidamide hydrochloride (7)






$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(3-trifluorophenyl)piperazine-1-carboximidamide hydrochloride (9)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(2-cyanophenyl)piperazine-1-carboximidamide hydrochloride (**12**)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(2,3-Dichlorophenyl)piperazine-1-carboximidamide hydrochloride (15)



$^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of 4-(3,4-Dichlorophenyl)piperazine-1-carboximidamide hydrochloride (16)

